In our study, the positive BRAF, KRAS and NRAS mutations in the bone marrow tumor DNA samples were 28/83 (34%), but it was 9/17 (53%) in the plasma cfDNA samples, which demonstrated a significantly higher detection rate. This evidence concerns the gene KRAS and neoplasm.